ACAD MEXC RealStocks
Own real ACAD shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 19:02:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Acadia Pharmaceuticals Inc. (ACAD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $18.11, with a market capitalization of $3.16B and a P/E ratio of 8.76. Over the past 52 weeks, its price has ranged from $15.86 to $30.96. This page covers its latest market performance, valuation, price trends and company information.
$3.16B | |
$18.22 | |
$18.52 | |
$18.02 | |
$18.37 | |
670.23K | |
2.16M | |
8.76 | |
$30.96 | |
$15.86 | |
-- | |
-- |
Acadia Pharmaceuticals Inc. (ACAD) is currently trading at $18.11 as of 2026-11-12 19:01:00, down 1.52% ($0.28) from the previous close of $18.37
During today's regular trading session, ACAD has traded between $18.02 and $18.52, with a trading volume of 670.23K shares. The current price is near the lower end of today's range.
Over the past seven days, Acadia Pharmaceuticals Inc. (ACAD) moved from $20.57 to $18.11, representing a decline of 11.95% ($2.46).
The stock traded between $15.86 and $22.63 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 5.02 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 14.9%
ACAD is currently trading at $18.11, placing it 14.9% of the way from its 52-week low of $15.86 to its 52-week high of $30.96. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 798 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Acadia Pharmaceuticals Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Acadia Pharmaceuticals Inc. (ACAD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ACAD, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ACAD shares and USD.
ACAD Shares to USD
1.00 ACAD shares = 18.111 USD
Calculations are estimates based on the latest available price and are for reference only.